赖戈奈截至2021年6月30日的现金职位

赖戈奈截至2021年6月30日的现金职位150.150.Lysogene
  • 现金和现金等价物1500万欧元1截至2021年6月30日

巴黎,法国 - 2021年7月23日在08:00 am CET - 赖戈涅(fr0013233475 - lys),靶向中枢神经系统(C亚搏全站app下载NS)疾病的第3阶段基因治疗平台公司报告其截至6月30日的现金职位。

截至2021年6月30日,现金和现金等价物总计1500万欧元1(与2021年3月31日相比,截至20.0百万欧元)。于2021年7月28日,莱尔索涅将获得280万美元(约240万欧元2)在与工业合作伙伴发生商业纠纷后支付,估计最大风险为500万美元。€420万2).剩余的120万欧元拨备在2020年财务报表中记录。

StéphaneDurantdes Aulnois,Lysogene的首席财务官评论:“公司严格的财务纪律帮助我们在上半年保护了我们的现金,并在很大程度上预测了纠纷的结果。因此,我们的财务能见度仍将持续到2022年上半年,我们正在积极评估不同的融资选择,以延长这一期限。”

1未经审计的图
22021年7月19日以欧元/美元汇率为1.1766

关于溶酶

Lysogene是一家专注于亚搏全站app下载中枢神经系统孤儿病治疗的基因治疗公司。该公司建立了一种独特的能力,能够将基因疗法递送到中枢神经系统,以治疗溶酶体疾病和其他中枢神经系统遗传疾病。与Sarepta Therapeutics, Inc.合作的MPS IIIA 2/3期临床试验正在进行中。GM1神经节脂肪沉积症的适应性临床试验正在进行中。亚博登录首页根据Lysogene与Sarepta Therapeutics, Inc.签署的协议,Sarepta Therapeutics, Inc.将持有LYS-SAF302在美国和欧洲以外市场的独家商业权利;和Lysogene将保持LYS-SAF302在欧洲的商业专有权。Lysogene还与SATT Conectus签订了一项全球独家许可协议,用于脆性X综合征(一种与自闭症相关的遗传疾病)的治疗候选基因疗法。亚搏全站app下载www.astridbowlby.com.

前瞻性陈述

本新闻稿可能包含某些前瞻性陈述,特别是本公司对其临床试验和现金跑道的进展。Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company’s control, (iii) clinical trial results, (iv) increased manufacturing costs and (v) potential claims on its products. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “objective”, “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, including in the 2020 universal registration document, registered with the French Markets Authorities on April 12, 2021, under number D.21-0296, and future filings and reports by the Company. Furthermore, theseforward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.

此新闻稿已在法语和英语中准备。如果两者之间存在任何差异
文本,法语版本应该取代。

联系人
Stéphanedurant des aulnois
首席财务官
stephane.durant-des-aulnois@lysogene.com
+33 1 41 43 03 99

Lysogene COVID-19更新

取得联系

如果你需要更多的帮助,请随时联系我们。

    回到顶部